Bruker Corporation (NASDAQ:BRKR)‘s stock had its “hold” rating reaffirmed by research analysts at Cowen and Company in a research note issued to investors on Friday. They currently have a $29.00 price objective on the medical research company’s stock. Cowen and Company’s target price suggests a potential downside of 13.02% from the company’s previous close.

BRKR has been the topic of several other research reports. Bank of America Corporation raised Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 price target on the stock in a report on Friday. BidaskClub cut Bruker Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. J P Morgan Chase & Co raised Bruker Corporation from an “underweight” rating to a “neutral” rating and set a $28.00 price target on the stock in a report on Friday. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and issued a $24.00 price target on shares of Bruker Corporation in a report on Tuesday, September 26th. Finally, Wells Fargo & Company cut Bruker Corporation from a “market perform” rating to an “underperform” rating in a report on Wednesday, July 12th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $28.09.

Bruker Corporation (NASDAQ BRKR) traded up $1.45 on Friday, reaching $33.34. 2,025,227 shares of the company’s stock were exchanged, compared to its average volume of 444,070. The stock has a market capitalization of $4.96 billion, a P/E ratio of 26.75 and a beta of 1.05.

Bruker Corporation (NASDAQ:BRKR) last released its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. The firm had revenue of $435.60 million during the quarter, compared to the consensus estimate of $415.45 million. Bruker Corporation had a return on equity of 25.93% and a net margin of 8.85%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share. equities research analysts predict that Bruker Corporation will post 1.12 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/03/bruker-corporations-brkr-hold-rating-reaffirmed-at-cowen-and-company.html.

In other news, CEO Frank H. Laukien bought 2,335 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were bought at an average cost of $27.39 per share, with a total value of $63,955.65. Following the purchase, the chief executive officer now directly owns 37,791,386 shares in the company, valued at $1,035,106,062.54. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total transaction of $631,198.17. Following the sale, the vice president now directly owns 60,524 shares in the company, valued at $1,813,904.28. The disclosure for this sale can be found here. 35.20% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in the business. Jennison Associates LLC acquired a new stake in Bruker Corporation during the 3rd quarter valued at $1,776,000. Prudential Financial Inc. raised its stake in Bruker Corporation by 292.8% during the 3rd quarter. Prudential Financial Inc. now owns 567,002 shares of the medical research company’s stock valued at $16,868,000 after purchasing an additional 422,660 shares during the period. Palisade Capital Management LLC NJ raised its stake in Bruker Corporation by 11.9% during the 3rd quarter. Palisade Capital Management LLC NJ now owns 563,496 shares of the medical research company’s stock valued at $16,764,000 after purchasing an additional 59,862 shares during the period. Bridge City Capital LLC raised its stake in Bruker Corporation by 8.7% during the 3rd quarter. Bridge City Capital LLC now owns 73,741 shares of the medical research company’s stock valued at $2,194,000 after purchasing an additional 5,908 shares during the period. Finally, Crossmark Global Holdings Inc. acquired a new stake in Bruker Corporation during the 3rd quarter valued at $259,000. 65.74% of the stock is currently owned by institutional investors.

About Bruker Corporation

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.